News Digest / Ticker: BHVN

Ticker: BHVN

08:41am, Monday, Sep 23, 2024

Biohaven Pharmaceuticals Soars 20% on Promising Clinical Trial Results for New Spinocerebellar Ataxia Treatment

Biohaven Pharmaceuticals (NYSE: BHVN) reports promising clinical trial results for troriluzole, aimed at treating Spinocerebellar Ataxia (SCA). The stock surged over 20% in premarket trading, signaling investor optimism in the biotech sector's growth.